Zobrazeno 1 - 10
of 46
pro vyhledávání: '"Tuyen K. Kiet"'
Autor:
Micah Naimark, C. Benjamin Ma, Tatiana Gajiu, Sarah L. Hall, Tuyen K. Kiet, Brian T. Feeley, Teddy T. Chung
Publikováno v:
Journal of Shoulder and Elbow Surgery. 24:179-185
Background Anatomic total shoulder arthroplasty (TSA) and reverse total shoulder arthroplasty (RTSA) are increasingly common procedures employed to treat arthritic conditions. Although TSA is a widely accepted procedure for glenohumeral arthritis wit
Autor:
Tuyen K. Kiet, Joan F. Hilton, John K. Chan, Daniela Matei, Daniel S. Kapp, Rashmi Ramasubbaiah, Kevin Blansit
Publikováno v:
Gynecologic Oncology. 133:568-574
Objective To determine the role of miR-378 as a biomarker for anti-angiogenic therapy response in ovarian cancer. Methods Expression of miR-378 was analyzed in ovarian cancer cell lines and human tumors vs. normal ovarian epithelial cells by qRT-PCR.
Autor:
A. Sherman, John K. Chan, Michael W. Rabow, Lee-may Chen, Rachel Ruskin, Carolyn Lefkowits, Tuyen K. Kiet
Publikováno v:
Gynecologic Oncology. 132:698-702
Objective To characterize symptom prevalence in gynecologic oncology outpatients and identify predictors of high symptom burden. Methods We performed a retrospective analysis of a convenience sample of symptom surveys from gynecologic oncology patien
Autor:
Kevin Blansit, Nichole Young-Lin, Daniel S. Kapp, Bradley J. Monk, John K. Chan, I. Amanam, Tuyen K. Kiet
Publikováno v:
The Oncologist. 19:299-304
Background Despite advances in cancer research, the majority of drug applications submitted to the U.S. Food and Drug Administration (FDA) are not approved. It is important to identify the concerns of the Oncologic Drugs Advisory Committee (ODAC) fro
Autor:
C. McClung, Kerri S. Bevis, James J. Java, Warner K. Huh, Kathleen N. Moore, L. Perry, John K. Chan, Tuyen K. Kiet, Angeles Alvarez Secord, J. Chapman, Rebecca A. Previs, Todd Tillmanns
Publikováno v:
Gynecologic Oncology. 132:531-536
Objective To develop a nomogram to predict overall survival (OS) in women with recurrent ovarian cancer treated with bevacizumab and chemotherapy. Methods A multicenter retrospective study was conducted. Potential prognostic variables included age; s
Autor:
Lee-may Chen, John K. Chan, Joshua G. Cohen, Stefanie Ueda, Chad A. Hamilton, Tuyen K. Kiet, Rebecca A. Brooks, Daniel S. Kapp, Jacob Y. Shin, A. Sherman
Publikováno v:
Gynecologic Oncology. 128:128-131
To determine the rate and factors associated with publication of plenary abstract presentations from the Society of Gynecologic Oncologists annual meeting.Plenary presentations were reviewed from 2000 to 2005. A PubMed search was performed to identif
Autor:
Tuyen K. Kiet, Jin Ge
Publikováno v:
Journal of general internal medicine. 32(4)
Autor:
John K. Chan, A. Sherman, Kathryn Osann, Lee-may Chen, Joshua G. Cohen, Patricia S. O'Sullivan, Tuyen K. Kiet, Daniel S. Kapp
Publikováno v:
Gynecologic Oncology. 125:8-13
Objectives While mentoring has been associated with research productivity, the specific characteristics of successful mentoring have not been well studied. Thus, we performed a case–control study to identify characteristics of successful mentoring
Autor:
Daniel S. Kapp, Thomas J. Herzog, Xinhua Yu, Bradley J. Monk, L. Hu, Kevin Blansit, Tuyen K. Kiet, John K. Chan
Objective. The objective of this study was to evaluate a cost-effectiveness strategy of bevacizumab in a subset of high-risk advanced ovarian cancer patients with survival benefit. Methods. A subset analysis of the International Collaboration on Ovar
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5e4badfe90838104784c1995511055e4
https://europepmc.org/articles/PMC4012959/
https://europepmc.org/articles/PMC4012959/
Autor:
Kevin Blansit, Tuyen K. Kiet, John K. Chan, Gabriel Wong, A. Sherman, Lilly Y.W. Bourguignon, Christine Earle
Publikováno v:
Gynecologic oncology. 132(3)
Background MicroRNAs have been implicated in tumorigenesis, drug resistance, and prognosis in cancer. We investigated the role of microRNA-21 ( miR-21 ) in regulating ovarian cancer drug resistance. Methods We used parental and cisplatin resistant ov